A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure

A first-in-human, phase 1, double blind, placebo-controlled, single ascending dose study examined the safety, tolerability, and exploratory efficacy of intravenous infusion of a recombinant growth factor, cimaglermin alfa, in patients with heart failure and left ventricular systolic dysfunction (LVS...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenihan, Daniel J., Anderson, Sarah A., Lenneman, Carrie Geisberg, Brittain, Evan, Muldowney, James A.S., Mendes, Lisa, Zhao, Ping Z., Iaci, Jennifer, Frohwein, Stephen, Zolty, Ronald, Eisen, Andrew, Sawyer, Douglas B., Caggiano, Anthony O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
CLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113538/
https://www.ncbi.nlm.nih.gov/pubmed/30167542
http://dx.doi.org/10.1016/j.jacbts.2016.09.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113538/
https://www.ncbi.nlm.nih.gov/pubmed/30167542
http://dx.doi.org/10.1016/j.jacbts.2016.09.005

Ejemplares similares